Offline dengan aplikasi Player FM !
Ep 9. Phase 2 trial of dapirolizumab pegol in SLE
Manage episode 331798536 series 3341497
Prof Richard Furie (New York, USA) and Dr Anastasia Madenidou evaluate the Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. They discuss the unique dose-response relationship endpoint used in this trial and the plans for Phase 3.
Read the paper here
Registration is open for BSR's Annual Conference. As the UK's leading rheumatology event, we bring together over 2,000 delegates for three days of learning, knowledge sharing, networking and innovation. Book your ticket today!
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
43 episode
Manage episode 331798536 series 3341497
Prof Richard Furie (New York, USA) and Dr Anastasia Madenidou evaluate the Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. They discuss the unique dose-response relationship endpoint used in this trial and the plans for Phase 3.
Read the paper here
Registration is open for BSR's Annual Conference. As the UK's leading rheumatology event, we bring together over 2,000 delegates for three days of learning, knowledge sharing, networking and innovation. Book your ticket today!
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
43 episode
Semua episode
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.